Two-thirds of people feel it is ‘unacceptable’ that life-changing medicines are available to patients in other countries before our own can get them, according to a survey conducted by Ipsos MRBI on behalf of Irish Pharmaceutical Healthcare Association (IPHA), the organisation that represents pharmaceutical innovators in Ireland.
As we near the end of the year, it’s a good time to look back on just some of the highlights of our public communications and advocacy.
With less than four months to Brexit Day, 29th March 2019, the pharmaceutical industry continues to require clarity and advice on its impact on Ireland, both from a practical and political perspective.
Professor Ian Greer, the new Vice Chancellor of Queen’s University Belfast gave an inspirational Annual Lecture of the Association of the British Pharmaceutical Industry at Stormont Buildings on 20th November.
Patients in Ireland are waiting more than twice as long as patients in other western European countries for access to many vital new medicines, figures from the Irish Pharmaceutical Healthcare Association (IPHA) have revealed.
IPHA Chief Executive Oliver O’Connor chaired the recent EFPIA Heads of Association meeting in Vienna, with vice Chair Anders Blanck from Sweden’s LEEM.
The meeting took place in Vienna to support Austrian pharma associations’ work with Austria’s current EU Presidency and to enable associations from smaller central and eastern European countries to attend.